These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 28796496)

  • 1. Discovery of Clinical Candidate N-((1S)-1-(3-Fluoro-4-(trifluoromethoxy)phenyl)-2-methoxyethyl)-7-methoxy-2-oxo-2,3-dihydropyrido[2,3-b]pyrazine-4(1H)-carboxamide (TAK-915): A Highly Potent, Selective, and Brain-Penetrating Phosphodiesterase 2A Inhibitor for the Treatment of Cognitive Disorders.
    Mikami S; Nakamura S; Ashizawa T; Nomura I; Kawasaki M; Sasaki S; Oki H; Kokubo H; Hoffman ID; Zou H; Uchiyama N; Nakashima K; Kamiguchi N; Imada H; Suzuki N; Iwashita H; Taniguchi T
    J Med Chem; 2017 Sep; 60(18):7677-7702. PubMed ID: 28796496
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of a Novel Series of Pyrazolo[1,5-a]pyrimidine-Based Phosphodiesterase 2A Inhibitors Structurally Different from N-((1S)-1-(3-Fluoro-4-(trifluoromethoxy)phenyl)-2-methoxyethyl)-7-methoxy-2-oxo-2,3-dihydropyrido[2,3-b]pyrazine-4(1H)-carboxamide (TAK-915), for the Treatment of Cognitive Disorders.
    Mikami S; Kawasaki M; Ikeda S; Negoro N; Nakamura S; Nomura I; Ashizawa T; Kokubo H; Hoffman ID; Zou H; Oki H; Uchiyama N; Hiura Y; Miyamoto M; Itou Y; Nakashima M; Iwashita H; Taniguchi T
    Chem Pharm Bull (Tokyo); 2017; 65(11):1058-1077. PubMed ID: 29093293
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TAK-915, a phosphodiesterase 2A inhibitor, ameliorates the cognitive impairment associated with aging in rodent models.
    Nakashima M; Suzuki N; Shiraishi E; Iwashita H
    Behav Brain Res; 2019 Dec; 376():112192. PubMed ID: 31521738
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of an Orally Bioavailable, Brain-Penetrating, in Vivo Active Phosphodiesterase 2A Inhibitor Lead Series for the Treatment of Cognitive Disorders.
    Mikami S; Sasaki S; Asano Y; Ujikawa O; Fukumoto S; Nakashima K; Oki H; Kamiguchi N; Imada H; Iwashita H; Taniguchi T
    J Med Chem; 2017 Sep; 60(18):7658-7676. PubMed ID: 28759228
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phosphodiesterase 2A Inhibitor TAK-915 Ameliorates Cognitive Impairments and Social Withdrawal in
    Nakashima M; Imada H; Shiraishi E; Ito Y; Suzuki N; Miyamoto M; Taniguchi T; Iwashita H
    J Pharmacol Exp Ther; 2018 Apr; 365(1):179-188. PubMed ID: 29440309
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of 1-[2-fluoro-4-(1H-pyrazol-1-yl)phenyl]-5-methoxy-3-(1-phenyl-1H-pyrazol-5-yl)pyridazin-4(1H)-one (TAK-063), a highly potent, selective, and orally active phosphodiesterase 10A (PDE10A) inhibitor.
    Kunitomo J; Yoshikawa M; Fushimi M; Kawada A; Quinn JF; Oki H; Kokubo H; Kondo M; Nakashima K; Kamiguchi N; Suzuki K; Kimura H; Taniguchi T
    J Med Chem; 2014 Nov; 57(22):9627-43. PubMed ID: 25384088
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Application of Structure-Based Design and Parallel Chemistry to Identify a Potent, Selective, and Brain Penetrant Phosphodiesterase 2A Inhibitor.
    Helal CJ; Arnold EP; Boyden TL; Chang C; Chappie TA; Fennell KF; Forman MD; Hajos M; Harms JF; Hoffman WE; Humphrey JM; Kang Z; Kleiman RJ; Kormos BL; Lee CW; Lu J; Maklad N; McDowell L; Mente S; O'Connor RE; Pandit J; Piotrowski M; Schmidt AW; Schmidt CJ; Ueno H; Verhoest PR; Yang EX
    J Med Chem; 2017 Jul; 60(13):5673-5698. PubMed ID: 28574706
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological characterization of a novel potent, selective, and orally active phosphodiesterase 2A inhibitor, PDM-631.
    Maehara S; Arakawa K; Hoshida K; Nagasue H; Chida N; Nakao K; Furusako S
    Eur J Pharmacol; 2017 Sep; 811():110-116. PubMed ID: 28587776
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The identification of a novel lead class for phosphodiesterase 2 inhibition by fragment-based drug design.
    Forster AB; Abeywickrema P; Bunda J; Cox CD; Cabalu TD; Egbertson M; Fay J; Getty K; Hall D; Kornienko M; Lu J; Parthasarathy G; Reid J; Sharma S; Shipe WD; Smith SM; Soisson S; Stachel SJ; Su HP; Wang D; Berger R
    Bioorg Med Chem Lett; 2017 Dec; 27(23):5167-5171. PubMed ID: 29113762
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Novel Phosphodiesterase 9A Inhibitor BI 409306 Increases Cyclic Guanosine Monophosphate Levels in the Brain, Promotes Synaptic Plasticity, and Enhances Memory Function in Rodents.
    Rosenbrock H; Giovannini R; Schänzle G; Koros E; Runge F; Fuchs H; Marti A; Reymann KG; Schröder UH; Fedele E; Dorner-Ciossek C
    J Pharmacol Exp Ther; 2019 Dec; 371(3):633-641. PubMed ID: 31578258
    [No Abstract]   [Full Text] [Related]  

  • 11. In vitro and in vivo characterisation of Lu AF64280, a novel, brain penetrant phosphodiesterase (PDE) 2A inhibitor: potential relevance to cognitive deficits in schizophrenia.
    Redrobe JP; Jørgensen M; Christoffersen CT; Montezinho LP; Bastlund JF; Carnerup M; Bundgaard C; Lerdrup L; Plath N
    Psychopharmacology (Berl); 2014 Aug; 231(16):3151-67. PubMed ID: 24577516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Phosphodiesterase 10A Selective Inhibitor TAK-063 Improves Cognitive Functions Associated with Schizophrenia in Rodent Models.
    Shiraishi E; Suzuki K; Harada A; Suzuki N; Kimura H
    J Pharmacol Exp Ther; 2016 Mar; 356(3):587-95. PubMed ID: 26675680
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [1,2,4]Triazolo[1,5-
    Tresadern G; Velter I; Trabanco AA; Van den Keybus F; Macdonald GJ; Somers MVF; Vanhoof G; Leonard PM; Lamers MBAC; Van Roosbroeck YEM; Buijnsters PJJA
    J Med Chem; 2020 Nov; 63(21):12887-12910. PubMed ID: 33105987
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The selective phosphodiesterase 9 (PDE9) inhibitor PF-04447943 (6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one) enhances synaptic plasticity and cognitive function in rodents.
    Hutson PH; Finger EN; Magliaro BC; Smith SM; Converso A; Sanderson PE; Mullins D; Hyde LA; Eschle BK; Turnbull Z; Sloan H; Guzzi M; Zhang X; Wang A; Rindgen D; Mazzola R; Vivian JA; Eddins D; Uslaner JM; Bednar R; Gambone C; Le-Mair W; Marino MJ; Sachs N; Xu G; Parmentier-Batteur S
    Neuropharmacology; 2011 Sep; 61(4):665-76. PubMed ID: 21619887
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of novel N-1 substituted pyrazolopyrimidinones as potent, selective PDE2 inhibitors.
    Morriello GJ; Dwyer MP; Chen Y; Ginetti AT; Xu S; Lu J; Abeywickrema P; Wang D; Crespo A; Cabalu TD; Wilson JE; Stachel SJ; Paone DV; Sinz C
    Bioorg Med Chem Lett; 2021 Jul; 44():128082. PubMed ID: 33991626
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of phosphodiesterase (1B, 2A, 9A and 10A) inhibitors on central nervous system cyclic nucleotide levels in rats and mice.
    Chen J; Zook D; Crickard L; Tabatabaei A
    Neurochem Int; 2019 Oct; 129():104471. PubMed ID: 31121256
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cyclic GMP-mediated memory enhancement in the object recognition test by inhibitors of phosphodiesterase-2 in mice.
    Lueptow LM; Zhan CG; O'Donnell JM
    Psychopharmacology (Berl); 2016 Feb; 233(3):447-56. PubMed ID: 26525565
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of potent selective bioavailable phosphodiesterase 2 (PDE2) inhibitors active in an osteoarthritis pain model. Part II: optimization studies and demonstration of in vivo efficacy.
    Plummer MS; Cornicelli J; Roark H; Skalitzky DJ; Stankovic CJ; Bove S; Pandit J; Goodman A; Hicks J; Shahripour A; Beidler D; Lu XK; Sanchez B; Whitehead C; Sarver R; Braden T; Gowan R; Shen XQ; Welch K; Ogden A; Sadagopan N; Baum H; Miller H; Banotai C; Spessard C; Lightle S
    Bioorg Med Chem Lett; 2013 Jun; 23(11):3443-7. PubMed ID: 23597790
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of binding and inhibitory properties of TAK-063, a novel phosphodiesterase 10A inhibitor.
    Harada A; Suzuki K; Kamiguchi N; Miyamoto M; Tohyama K; Nakashima K; Taniguchi T; Kimura H
    PLoS One; 2015; 10(3):e0122197. PubMed ID: 25815469
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design and discovery of 6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one (PF-04447943), a selective brain penetrant PDE9A inhibitor for the treatment of cognitive disorders.
    Verhoest PR; Fonseca KR; Hou X; Proulx-Lafrance C; Corman M; Helal CJ; Claffey MM; Tuttle JB; Coffman KJ; Liu S; Nelson F; Kleiman RJ; Menniti FS; Schmidt CJ; Vanase-Frawley M; Liras S
    J Med Chem; 2012 Nov; 55(21):9045-54. PubMed ID: 22780914
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.